Price Action Report: What’s Ahead for Progenics Pharmaceuticals, Inc. After Today’s Significant Increase?

Price Action Report: What's Ahead for Progenics Pharmaceuticals, Inc. After Today's Significant Increase?

The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a huge mover today! About 326,325 shares traded hands. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 57.55% since April 21, 2016 and is uptrending. It has outperformed by 52.22% the S&P500.
The move comes after 5 months positive chart setup for the $577.22 million company. It was reported on Nov, 23 by Barchart.com. We have $8.50 PT which if reached, will make NASDAQ:PGNX worth $17.32M more.

Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on March, 10. They expect $-0.23 EPS, down 130.00% or $0.13 from last year’s $-0.1 per share. After $0.52 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -144.23% negative EPS growth.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage

Out of 4 analysts covering Progenics Pharm (NASDAQ:PGNX), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 5 analyst reports since August 6, 2015 according to StockzIntelligence Inc. On Thursday, October 27 the stock rating was initiated by Aegis Capital with “Buy”. The company was maintained on Thursday, August 6 by Brean Capital. Needham maintained Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Friday, August 7. Needham has “Buy” rating and $11 price target. The firm has “Buy” rating given on Friday, August 7 by Zacks. Jefferies upgraded it to “Buy” rating and $9 target price in Friday, October 23 report.

According to Zacks Investment Research, “Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.”

Insitutional Activity: The institutional sentiment increased to 1.17 in Q2 2016. Its up 0.41, from 0.76 in 2016Q1. The ratio increased, as 25 funds sold all Progenics Pharmaceuticals, Inc. shares owned while 29 reduced positions. 12 funds bought stakes while 29 increased positions. They now own 58.35 million shares or 1.82% less from 59.43 million shares in 2016Q1.
Bnp Paribas Arbitrage owns 2,559 shares or 0% of their US portfolio. Clear Harbor Asset Management Lc has invested 0.05% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Mufg Americas Corp has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Stifel Corp reported 23,451 shares or 0% of all its holdings. Sabby Mgmt Ltd Liability Co holds 0.04% or 174,900 shares in its portfolio. Horizon Kinetics Lc holds 0.01% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 67,200 shares. Da Davidson And Co owns 1,000 shares or 0% of their US portfolio. The New York-based Goldman Sachs Grp has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Kennedy Capital Inc last reported 0.05% of its portfolio in the stock. Wells Fargo And Mn accumulated 0% or 72,956 shares. Phocas Corp reported 649,295 shares or 0.2% of all its holdings. Fmr Limited Liability has 3.34 million shares for 0% of their US portfolio. Rhumbline Advisers last reported 80,988 shares in the company. Moreover, Great West Life Assurance Can has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 12,200 shares. Schwab Charles Invest Mgmt last reported 0% of its portfolio in the stock.

Another recent and important Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news was published by Fool.com which published an article titled: “Why Progenics Pharmaceuticals, Inc. Shares Soared Today” on July 20, 2016.

PGNX Company Profile

Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment